ClinicalTrials.gg
RecruitingNCT07036692Updated Nov 12, 2026

The FaibaGo Study - Long-Term Weight Reduction Via Low-Threshold Intervention

An interventional study of Placebo and FibreGum in Nutritional and Metabolic Diseases and Overweight, sponsored by University of Bern. Recruiting at 1 site in Switzerland. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionOverweightRegistry: Nutritional and Metabolic DiseasesReclassifiedWhy we changed it
Registry
Nutritional and Metabolic Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Overweight
Why
  1. The study's listed conditions name Overweight, a narrower term within Nutritional and Metabolic Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Bern · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Overweight with a site in Switzerland — 7 open to participants now, 13 under way, 4 of them phase 3. Overweight · Switzerland.

Planned enrollment
6th of 29
120 · median 76
Started
2025
with 6 others
No phase
20 of 38
5 open now
Primary completion
2027-10
later than 5 of 12 live
Registered
29th of 38
by date

Among the 38 studies in Overweight with a site in Switzerland, this one is the 6th largest by planned enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 29th registered.

Overweight

3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.

Browse Overweight studies →

Open to participants now

7 of the 38 studies in Overweight with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Overweight with a site in Switzerland, or all of them as a file.
02

Study summary

The main aim of this study is to assess the effect of a chewing gum containing galactooligosaccharides (GOS) on the body mass index (BMI), the metabolism and the oral and intestinal microbiomes in a population of overweight adults.

03

Conditions studied

  • Nutritional and Metabolic Diseases
  • Overweight

Browse trials for

Keywords

  • Overweight
  • Chewing gum
  • Galactooligosaccharides
  • GOS (Galactooligosaccharides)
  • Oral microbiome
  • Intestinal microbiome
04

In context

Overweight Reclassified

3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.

This study's planned enrollment of 120 is above the median of 78 across 3,142 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.

Compared within Overweight, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutritional and Metabolic Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (IC) according to ICH/GCP regulations prior to any study-specific procedures
  • Adults aged ≥ 25 years
  • Overweight as determined by a > 25 kg/m2
  • Metabolic risk factor: at least one of the following criteria:

    i. ≥ 5.7% ii. Elevated liver enzymes (ALAT, ASAT, Gamma-Glutamyltransferase (gGT) at least one above normal range of the assay used in the respective laboratory) iii. LDL-cholesterol > 3.0 mmol/l iv. Triglycerides > 1.7 mmol/l

  • Ability and willingness to follow the study protocol (e.g., cognitive capacity for compliance, gum chewing, faecal sample collection)
  • Access to a scale to self-report weight
  • Access and willing to use an electronic device (e.g., mobile phone, computer or tablet)
  • Laboratory assessments of blood parameters were performed within a reasonable timeframe prior to the eligibility assessment, as determined by the PI.

Exclusion criteria

Exclusion Criteria:

  • Systemic antibiotic use within the last 2 months
  • History of bariatric surgery
  • Initiation or dose adjustment of pharmaceutical treatment for dyslipidemia or hyperglycemia within the last 3 months or during the study (e.g., metformin, statins, SGLT2 inhibitors)
  • Use of prebiotic or probiotic supplementation (duration >1 month) within the last 6 weeks (at PI's discretion, based on medication summary of TP)
  • Medical weight management treatments within the last year (e.g., Glucagon-Like Peptide-1 (GLP-1) agonists)
  • Recent (\<1 month) dose adjustment, initiation or termination of proton pump inhibitors use (e.g., pantoprazole, omeprazole)
  • Professionally supervised intensive (>6 months of ongoing supervision) weight management treatments (e.g., structured nutrition counselling) within the last year (at the PI's discretion)
  • Diagnosis of Type 1 or Type 2 diabetes requiring bolus insulin therapy or frequent dose adjustments in base line insulin
  • Regular alcohol consumption exceeding two (women) or three (men) standard units (10 g of pure alcohol) per day
  • Consumption of more than one nicotine product (e.g., (e-)cigarette, gum) per month
  • Regular drug abuse (once per week over the past 4 months)
  • Any stage of known pregnancy or lactation period (self-reported)
  • Active cancer or recent cancer treatment (within the last 4 months)
  • Chronic, active inflammatory diseases (e.g., inflammatory bowel disease, rheumatoid arthritis)
  • Severe gastrointestinal disorders (e.g., celiac disease, short bowel syndrome, gastroparesis)
  • Known eating disorder (medically diagnosed)
  • Participation in another investigation with an drug within the 30 days preceding randomisation
  • Dependency from the Sponsor-Investigator
  • Last visit with TP > 22 days prior to eligibility assessment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Chewing gum containing maltitol powder

    Dietary Supplement: Placebo

  • Experimental
    Interventional

    Chewing gums containing galactooligosaccharides (GOS)

    Dietary Supplement: FibreGum

  • No intervention
    No-treatment control

    No chewing-gums

Interventions

  • Dietary supplementPlacebo

    To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.

  • Dietary supplementFibreGum

    To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.

07

What researchers measure

Primary outcomes

  1. Change in the Body Mass Index (BMI) during intervention

    Difference in the BMI measured at intervention start and intervention completion

    Time frame: 4 months

Secondary outcomes

  1. Systolic blood pressures change during intervention

    Difference in systolic blood pressure (mm Hg) between intervention completion and intervention start.

    Time frame: 4 months

  2. Diastolic blood pressures changes during intervention

    Difference in diastolic blood pressure (mm Hg) between intervention completion and intervention start.

    Time frame: 4 months

  3. Self-reported weight changes during intervention

    Difference in self-reported weight (kg) between intervention completion and intervention start.

    Time frame: 4 months

  4. Self-reported weight changes during follow-up

    Difference in self-reported weight (kg) between end of follow-up period and intervention completion.

    Time frame: 2 months from intervention completion (month 4) to end of follow-up period (month 6)

  5. Waist circumference changes during intervention

    Difference in waist circumference (cm) between between intervention completion and intervention start.

    Time frame: 4 months

  6. Waist circumference changes during follow-up

    Difference in waist circumference (cm) between end of follow-up period and intervention completion.

    Time frame: 2 months from intervention completion (month 4) to end of follow-up period (month 6)

  7. Fasting blood glucose change during intervention

    Difference in fasting blood glucose (mg/dL or mmol/L) between intervention completion and intervention start.

    Time frame: 4 months

  8. Fasting insulin change during intervention

    Difference in fasting insulin (mIU/mL) between intervention completion and intervention start.

    Time frame: 4 months

  9. HOmeostatic Model Assessment of Insulin Resistance (HOMA-IR) index change during intervention

    Difference in Homeostatic Model Assessment of Insulin Resistance Index (min:0 - max:10) between intervention completion and intervention start. Lower scores mean better outcome.

    Time frame: 4 months

  10. Hemoglobin A1c (HbA1c) change during intervention

    Difference in HbA1c (mmol/mol) between intervention completion and intervention start.

    Time frame: 4 months

  11. Cholesterol change during intervention

    Difference in Cholesterol (mg/dL) between intervention completion and intervention start.

    Time frame: 4 months

  12. Triglyceride change during intervention

    Difference in Triglyceride (mg/dL) between intervention completion and intervention start.

    Time frame: 4 months

  13. High-density lipoproteins (HDL) change during intervention

    Difference in HDL (mg/dL) between intervention completion and intervention start.

    Time frame: 4 months

  14. Low-density lipoproteins (LDL) change during intervention

    Difference in LDL (mg/dL) between intervention completion and intervention start.

    Time frame: 4 months

  15. Neutrophils change during intervention

    Difference in Neutrophils count (%) between intervention completion and intervention start.

    Time frame: 4 months

  16. Lymphocytes change during intervention

    Difference in Lymphocytes count (%) between intervention completion and intervention start.

    Time frame: 4 months

  17. Monocyte change during intervention

    Difference in Monocytes count (%) between intervention completion and intervention start.

    Time frame: 4 months

  18. Eosinophils change during intervention

    Difference in Eosinophils count (%) between intervention completion and intervention start.

    Time frame: 4 months

  19. Basophils change during intervention

    Difference in Basophils count (%) between intervention completion and intervention start.

    Time frame: 4 months

  20. Alanine Aminotransferase (ALAT) change during intervention

    Difference in ALAT (U/L) between intervention completion and intervention start.

    Time frame: 4 months

  21. Aspartate Aminotransferase (ASAT) change during intervention

    Difference in ASAT (U/L) between intervention completion and intervention start.

    Time frame: 4 months

  22. Calcifediol (25OH-Vitamin D3) change during intervention

    Difference in Calcifediol (nmol/L) between intervention completion and intervention start.

    Time frame: 4 months

  23. Thyroid-Stimulating Hormone (TSH) change during intervention

    Difference in TSH (mU/L) between intervention completion and intervention start.

    Time frame: 4 months

  24. Ferritin change during intervention

    Difference in Ferritin (μg/L) between intervention completion and intervention start.

    Time frame: 4 months

  25. Proteinuria change during intervention

    Difference in Proteinuria (g/24h) between intervention completion and intervention start.

    Time frame: 4 months

  26. Oral microbiome change during intervention

    Change in oral microbiota as assessed by metagenomic sequencing from oral washes between intervention completion and intervention start.

    Time frame: 4 months

  27. Gut microbiome change during intervention

    Change in intestinal microbiota-composition as assessed by metagenomic sequencing from stool samples between intervention completion and intervention start.

    Time frame: 4 months

  28. Breath metabolome change during intervention

    Change in volatile compounds present in the breath detected by secondary electrospray ionization (SESI) source in combination with a high-resolution mass spectrometry (HR-MS) between intervention completion and intervention start.

    Time frame: 4 months

  29. Body composition change (body fat) during intervention

    Change in body fat between intervention completion and intervention start.

    Time frame: 4 months

  30. Body composition change (lean mass) during intervention

    Change in lean mass between intervention completion and intervention start.

    Time frame: 4 months

  31. Change in in-vitro response of faecal microbiota (alpha diversity) to a panel of prebiotic compounds during intervention

    Change in community diversity (alpha diversity) assessed by metagenomic sequencing between intervention completion and intervention start.

    Time frame: 4 months

  32. Change in in-vitro response of faecal microbiota (beta diversity) to a panel of prebiotic compounds during intervention

    Change in composition (beta diversity, differential abundance) assessed by metagenomic sequencing between intervention completion and intervention start.

    Time frame: 4 months

08

Study locations

1 of 1 sites recruiting
  • Department of Biomedical Research, University of Bern
    Bern, 3010, Switzerland
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 1,314 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 24 months is above that.

Counting every sponsor, half of 1,427 studies reached it within 17 months; a quarter within 7 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Oct 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jun 25, 2025
StartActual
Oct 9, 2025
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 12, 2026
Study completion
Dec 2026→Dec 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 2026→Oct 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07036692
Lead sponsor
University of Bern
Collaborators
DCB Research AG
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Oct 9, 2025
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Maria L Balmer, Prof. med.
Contact
maria.balmer@unibe.ch
031 632 26 19 ext. 0041
Janina N Zünd, PhD
Contact
janina.zuend@unibe.ch
031 632 26 19 ext. 0041
Maria L Balmer, Prof. med.
principal investigator · Department of Biomedical Research, University of Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion